EUVIMEDEUVIMED entdecken
Crossref

Assessment of L-carnitine as a therapeutic agent for cancer-related fatigue in patients receiving platinum-based chemotherapy regimens; a parallel-group, randomized, double-blind clinical trial study

Parisa Delkash, Ali Parsa, Zahra Abbasi, Sahar Kavand, Sina Homaee, Farnaz Hadizade, Farnaz Saberian, Mahmoud Dehghani-ghorbi

Journal of Preventive Epidemiology · 21.09.2025 · 11 (1) · e39286

DOI: 10.34172/jpe.2025.39286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Preventive Epidemiology, online erschienen am 21.09.2025. Verfasst von Parisa Delkash und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cancer-related fatigue (CRF) is a common and debilitating symptom that significantly impacts patients’ quality of life and daily functioning. L-carnitine, a naturally occurring amino acid derivative involved in energy metabolism, has been suggested as a potential therapeutic agent to alleviate fatigue.

Objectives

This study aimed to assess the effectiveness of L-carnitine supplementation in fatigue management among cancer patients. Patients and Methods: This randomized, double-blind clinical trial conducted at Imam Hossein hospital enrolled 90 cancer patients receiving platinum-based chemotherapy between September 2024 and June 2025. Participants were randomly assigned to receive either L-carnitine or a placebo, with 45 patients in each group. Eligible patients were over 18 years, experiencing fatigue, and provided informed written consent. Demographic and clinical data were collected by a trained researcher who was blinded to the group allocation. Fatigue levels were assessed using the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) questionnaire at baseline, and at four and eight weeks. The primary outcome was the comparison of FACIT-F scores both between and within the L-carnitine and control groups throughout the study.

Results

The study results showed that although the fatigue scores were similar between the L-carnitine and control groups at baseline, the L-carnitine group experienced a significantly greater improvement in fatigue over time. By the fourth week, participants receiving L-carnitine exhibited significantly higher improvements in fatigue scores compared to the control group, and this advantage was even more pronounced by the eighth week. Additionally, the L-carnitine group continued to show a meaningful increase in fatigue score improvements between the fourth and eighth weeks, while the control group’s scores remained relatively stable during that period.

Conclusion

L-carnitine appears to be a safe and promising adjunctive therapy for managing CRF in patients receiving platinum-based chemotherapy. Incorporation of L-carnitine supplementation into supportive care protocols may improve patient outcomes and quality of life. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials with code (identifier: IRCT20241112063688N1; https://irct.behdasht.gov.ir/trial/80160), and ethical code from Shahid Beheshti University of Medical Sciences (IR.SBMU.MSP.REC.1403.289; https://ethics.research.ac.ir/ EthicsProposalView.php?id=492026).

Zitieren

APA

Delkash, P., Parsa, A., Abbasi, Z., Kavand, S., Homaee, S., Hadizade, F., Saberian, F., & Dehghani-ghorbi, M. (2025). Assessment of L-carnitine as a therapeutic agent for cancer-related fatigue in patients receiving platinum-based chemotherapy regimens; a parallel-group, randomized, double-blind clinical trial study. Journal of Preventive Epidemiology, 11(1), e39286. https://doi.org/10.34172/jpe.2025.39286

Vancouver

Delkash P, Parsa A, Abbasi Z, Kavand S, Homaee S, Hadizade F, et al. Assessment of L-carnitine as a therapeutic agent for cancer-related fatigue in patients receiving platinum-based chemotherapy regimens; a parallel-group, randomized, double-blind clinical trial study. Journal of Preventive Epidemiology. 2025;11(1):e39286. doi:10.34172/jpe.2025.39286

BibTeX
@article{Delkash2025,
  author = {Delkash, Parisa and Parsa, Ali and Abbasi, Zahra and Kavand, Sahar and Homaee, Sina and Hadizade, Farnaz and Saberian, Farnaz and Dehghani-ghorbi, Mahmoud},
  title = {Assessment of L-carnitine as a therapeutic agent for cancer-related fatigue in patients receiving platinum-based chemotherapy regimens; a parallel-group, randomized, double-blind clinical trial study},
  journal = {Journal of Preventive Epidemiology},
  year = {2025},
  volume = {11},
  number = {1},
  pages = {e39286},
  doi = {10.34172/jpe.2025.39286}
}
Kostenlos starten →